\u201c\u0160is ir bijis lielisks gads ar lieliem p\u0101rdo\u0161anas apjomiem, m\u0113s sp\u0113j\u0101m sasniegt savus strat\u0113\u0123iskos m\u0113r\u0137us. T\u0101d\u0113j\u0101di l\u012bdz finan\u0161u gada beig\u0101m es sagaidu, ka pieaugums b\u016bs ap 20%,\u201d st\u0101sta Norameda Latvijas fili\u0101les vad\u012bt\u0101js Erv\u012bns Groms.<\/p>\n
Onkolo\u0123isko produktu l\u012bnija bija galvenais Norameda pozit\u012bvo rezult\u0101tu veicin\u0101t\u0101js Latvij\u0101. Un tas nav br\u012bnums, jo onkolo\u0123isk\u0101 medic\u012bna ir galvenais farm\u0101cijas tirgus virz\u012bt\u0101jsp\u0113ks vis\u0101 pasaul\u0113.<\/p>\n
E. Groms piemin\u0113ja ar\u012b veiksm\u012bgu jauno produktu lai\u0161anu tirg\u016b 2022. gad\u0101. Ta\u010du, k\u0101 vienm\u0113r, labas un ilgsto\u0161as attiec\u012bbas ar partneriem un pat\u0113r\u0113t\u0101jiem ir viens no galvenajiem faktoriem, kas ietekm\u0113 izaugsmi gadu no gada.<\/p>\n
\u201cLai gan var\u0113tu teikt, ka \u0161is gads ir bijis izaicin\u0101jumiem pilns, vissvar\u012bg\u0101k\u0101 mums ir tirgus stabilit\u0101te. \u0160ogad nopietnas tirgus izmai\u0146as nav notiku\u0161as, un tas pal\u012bdz saglab\u0101t stabilu izaugsmi,\u201d st\u0101sta Norameda Latvijas fili\u0101les vad\u012bt\u0101js.<\/p>\n
P\u0113c E. Groma teikt\u0101, Latvij\u0101 vesel\u012bbas sist\u0113ma atguv\u0101s no pand\u0113mijas sal\u012bdzino\u0161i \u0101tri, un tas b\u016btiski neietekm\u0113ja Norameda darb\u012bbu. Tom\u0113r dr\u012bzum\u0101 ir gaid\u0101ms jauns Covid vilnis.<\/p>\n
\u201cKar\u0161 Ukrain\u0101 ir posto\u0161s, un tas liel\u0101k\u0101 vai maz\u0101k\u0101 m\u0113r\u0101 ietekm\u0113 visas Eiropas valstis. Piem\u0113ram, pie mums Latvij\u0101 ir j\u016btams da\u017eu medikamentu tr\u016bkums, cenas pieaug, jo \u012bpa\u0161i bezrecep\u0161u z\u0101l\u0113m, ir ar\u012b pieg\u0101\u017eu trauc\u0113jumi, ta\u010du ar\u012b p\u0101r\u0113j\u0101s CAE valst\u012bs nav cit\u0101d\u0101k,\u201d nor\u0101da E. Groms.<\/p>\n
Bezrecep\u0161u z\u0101\u013cu un uztura bag\u0101tin\u0101t\u0101ju cenu pieaugums ir gaid\u0101ms ar\u012b n\u0101kamgad. Par vienu no liel\u0101kajiem iemesliem tam var\u0113tu b\u016bt b\u016btiska infl\u0101cija Latvij\u0101.<\/p>\n
Tom\u0113r Norameda Latvijas fili\u0101les vad\u012bt\u0101js ir optimistisks \u2013 vi\u0146\u0161 sagaida stabilu izaugsmi ar\u012b turpm\u0101k.<\/p>\n
“M\u0113s jau zin\u0101m, ka n\u0101kamgad m\u0113s laid\u012bsim tirg\u016b da\u017eus jaunus produktus. Starp m\u016bsu izplat\u012bt\u0101jiem ar\u012b ir nov\u0113rojama izaugsme; attiec\u012bbas k\u013c\u016bst stipr\u0101kas gan ar partneriem, gan \u0101rstiem. T\u0101d\u0113\u013c j\u0101, neskatoties uz kop\u0113jo situ\u0101ciju, es esmu p\u0101rliecin\u0101ts par Norameda Latvij\u0101 un ceru sasniegt v\u0113l liel\u0101ku pievienoto v\u0113rt\u012bbu un iepriecino\u0161us skait\u013cus,\u201d saka E. Groms.<\/p>\n","protected":false},"excerpt":{"rendered":"
\u201c\u0160is ir bijis lielisks gads ar lieliem p\u0101rdo\u0161anas apjomiem, m\u0113s sp\u0113j\u0101m sasniegt savus strat\u0113\u0123iskos m\u0113r\u0137us. T\u0101d\u0113j\u0101di l\u012bdz finan\u0161u gada beig\u0101m es sagaidu, ka pieaugums b\u016bs ap 20%,\u201d st\u0101sta Norameda Latvijas fili\u0101les vad\u012bt\u0101js Erv\u012bns Groms. Onkolo\u0123isko produktu l\u012bnija bija galvenais Norameda pozit\u012bvo rezult\u0101tu veicin\u0101t\u0101js Latvij\u0101. Un tas nav br\u012bnums, jo onkolo\u0123isk\u0101 medic\u012bna ir galvenais farm\u0101cijas tirgus […]<\/p>\n","protected":false},"author":220,"featured_media":8040,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"_links_to":"","_links_to_target":""},"categories":[141],"tags":[],"_links":{"self":[{"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/posts\/8059"}],"collection":[{"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/users\/220"}],"replies":[{"embeddable":true,"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/comments?post=8059"}],"version-history":[{"count":0,"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/posts\/8059\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/media\/8040"}],"wp:attachment":[{"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/media?parent=8059"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/categories?post=8059"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/tags?post=8059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}